ClinicalTrials.gg

Program

SKY-0515

A development code.

Its studies are mostly in Huntington Disease, led by Skyhawk Therapeutics.

Furthest: phase 3, since Mar 6, 20252 company-led studies, 2 open or runningNext primary completion: May 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Skyhawk Therapeutics22 open or runningphase 3since Mar 6, 2025Mar 6, 2025May 2027phase 3 · NCT06873334

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 6, 2025First study: phase 3 study in Huntington DiseaseFirst studyNCT06873334 · 120 enrolled · Australia, New Zealand
  2. Apr 3, 2026Phase 3 study in Huntington DiseaseNCT07537075 · 500 planned · Australia, New Zealand

Ahead

  1. May 2027Primary completion: phase 3 study in Huntington DiseaseNCT06873334
  2. Dec 2029Primary completion: phase 3 study in Huntington DiseaseNCT07537075

TargetBeta

HTT →read by rule
“This clinical trial aims to evaluate the safety, pharmacodynamics, and efficacy of SKY-0515, a novel, orally-administered small molecule mRNA-splicing modulator for treating Huntington's Disease (HD).”study text, by rule · the study

Other programs on HTT

ProgramCompanyFurthest phaseStudies
L-(+)-methylenetetrahydrofolic acidruleisofol-medical-abphase 35
votoplamNovartisphase 33

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07537075Huntington Disease · Australia, New Zealand3By invitationDec 2029500
NCT06873334Huntington Disease · Australia, New Zealand3Active, not recruitingMay 2027120

How it is read

Names in the registry

  • “SKY-0515”, 2 entries

Codes read as this program: SKY0515.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.